JP2015513544A5 - - Google Patents

Download PDF

Info

Publication number
JP2015513544A5
JP2015513544A5 JP2014559183A JP2014559183A JP2015513544A5 JP 2015513544 A5 JP2015513544 A5 JP 2015513544A5 JP 2014559183 A JP2014559183 A JP 2014559183A JP 2014559183 A JP2014559183 A JP 2014559183A JP 2015513544 A5 JP2015513544 A5 JP 2015513544A5
Authority
JP
Japan
Prior art keywords
chem
glp
compound according
peptide
amide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014559183A
Other languages
Japanese (ja)
Other versions
JP2015513544A (en
JP6300735B2 (en
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/053796 external-priority patent/WO2013127779A1/en
Publication of JP2015513544A publication Critical patent/JP2015513544A/en
Publication of JP2015513544A5 publication Critical patent/JP2015513544A5/ja
Application granted granted Critical
Publication of JP6300735B2 publication Critical patent/JP6300735B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (15)

一般式IのGLP-1化合物:
R1-(NHXaa1)-Xaa2-(OHis)-(GLP-1ペプチド)(式I)
[式中、
GLP-1ペプチドは、GLP-1(8-37)(配列番号1)、またはGLP-1(8-37)(配列番号1)と比較して最大で9個のアミノ酸の変化を有するその類似体であり、
R1は、低級アルキルであり、
(NHXaa1)は、アミノ酸であり、
Xaa2は、アミノ酸であり、
(OHis)は、式Chem.1
Chem.1:
Figure 2015513544
 のイミダゾール-乳酸のラジカルである]
またはその薬学的に許容される塩、アミド、もしくはエステル。 GLP-1 compounds of general formula I:
R1- (NHXaa1) -Xaa2- (OHis)-(GLP-1 peptide) (Formula I)
[Where
GLP-1 peptide has GLP-1 (8-37) (SEQ ID NO: 1), or its analog with up to 9 amino acid changes compared to GLP-1 (8-37) (SEQ ID NO: 1) Body,
R1 is lower alkyl,
(NHXaa1) is an amino acid,
Xaa2 is an amino acid,
(OHis) is the formula Chem.1
Chem. 1:
Figure 2015513544
 Is an imidazole-lactic acid radical]
Or a pharmaceutically acceptable salt, amide, or ester thereof. Xaa2と(OHis)との間の結合が、エステル結合である、請求項1に記載の化合物。   2. The compound according to claim 1, wherein the bond between Xaa2 and (OHis) is an ester bond. i)(NHXaa1)とXaa2との間、およびii)(OHis)と(GLP-1ペプチド)との間の結合が、アミド結合であり、R1が、(NHXaa1)のα-アミノ基に付着している、請求項1または2に記載の化合物。   The bond between i) (NHXaa1) and Xaa2, and ii) (OHis) and (GLP-1 peptide) is an amide bond, and R1 is attached to the α-amino group of (NHXaa1). The compound according to claim 1 or 2. R1が、メチルである、請求項1から3のいずれか一項に記載の化合物。   4. The compound according to any one of claims 1 to 3, wherein R1 is methyl. (NHXaa1)が、Gly、Val、またはIleである、請求項1から4のいずれか一項に記載の化合物。   The compound according to any one of claims 1 to 4, wherein (NHXaa1) is Gly, Val, or Ile. Xaa2が、Valである、請求項1から5のいずれか一項に記載の化合物。   6. The compound according to any one of claims 1 to 5, wherein Xaa2 is Val. GLP-1ペプチドが、少なくとも1つのアルブミン結合側鎖を含む誘導体である、請求項6に記載の化合物。   7. A compound according to claim 6, wherein the GLP-1 peptide is a derivative comprising at least one albumin binding side chain. GLP-1ペプチドが、
i)26位もしくは27位に付着した1つのアルブミン結合側鎖;または
ii)a)18位および31位のそれぞれ、b)26位および37位のそれぞれ、もしくはc)18位および26位のそれぞれに付着した1つのアルブミン結合側鎖
を有する誘導体であり、位置の付番は、GLP-1(8-37)(配列番号1)を意味する、請求項7に記載の化合物。 GLP-1 peptide
i) one albumin binding side chain attached at position 26 or 27; or
ii) Derivatives with one albumin binding side chain attached to a) positions 18 and 31, respectively, b) positions 26 and 37, or c) positions 18 and 26, respectively. The compound according to claim 7, wherein the number means GLP-1 (8-37) (SEQ ID NO: 1). Chem.51、Chem.52、Chem.53、Chem.54、Chem.55、およびChem.56から選択される化合物、またはその薬学的に許容される塩、アミドもしくはエステル：
Figure 2015513544
Figure 2015513544
Figure 2015513544
Figure 2015513544
Figure 2015513544
Figure 2015513544
 A compound selected from Chem. 51, Chem. 52, Chem. 53, Chem. 54, Chem. 55, and Chem. 56, or a pharmaceutically acceptable salt, amide or ester thereof:
Figure 2015513544
Figure 2015513544
Figure 2015513544
Figure 2015513544
Figure 2015513544
Figure 2015513544
 Chem.21、Chem.22、Chem.23、Chem.24、およびChem.25から選択される化合物、またはその薬学的に許容される塩、アミドもしくはエステル：
Figure 2015513544
Figure 2015513544
Figure 2015513544
Figure 2015513544
Figure 2015513544
 A compound selected from Chem. 21, Chem. 22, Chem. 23, Chem. 24, and Chem. 25, or a pharmaceutically acceptable salt, amide or ester thereof:
Figure 2015513544
Figure 2015513544
Figure 2015513544
Figure 2015513544
Figure 2015513544
 Chem.41、Chem.42、Chem.43、およびChem.44から選択される化合物、またはその塩、アミドもしくはエステル：
Figure 2015513544
 A compound selected from Chem. 41, Chem. 42, Chem. 43, and Chem. 44, or a salt, amide or ester thereof:
Figure 2015513544
 医薬として使用するための、請求項1から10のいずれか一項に記載の化合物。   11. A compound according to any one of claims 1 to 10 for use as a medicament. 摂食障害、心血管疾患、胃腸疾患、糖尿病性合併症、重篤疾患、および/もしくは多嚢胞性卵巣症候群から成る群から選択される全ての形態の糖尿病および関連する疾患の治療および/もしくは予防において使用するため;ならびに/または脂質パラメーターを改善するため、β-細胞機能を改善するため、ならびに/または糖尿病性疾患の進行を遅延もしくは予防するための、請求項1から10のいずれか一項に記載の化合物。 Eating disorders, cardiovascular disease, gastrointestinal diseases, diabetic complications, severe diseases, and / or the treatment and / or prevention of polycystic all forms of diabetes and related disease selected from the group consisting of ovary syndrome And / or for improving lipid parameters, for improving β-cell function, and / or for delaying or preventing the progression of diabetic disease. Compound described in 1. 摂食障害、心血管疾患、胃腸疾患、糖尿病性合併症、重篤疾患、および多嚢胞性卵巣症候群から成る群から選択される全ての形態の糖尿病および関連する疾患を治療もしくは予防するため;ならびに/または脂質パラメーターを改善するため、β-細胞機能を改善するため、ならびに/または糖尿病性疾患の進行を遅延もしくは予防するための、請求項1から10のいずれか一項に記載の化合物を含む医薬組成物。 Eating disorders, cardiovascular disease, gastrointestinal diseases, diabetic complications, severe diseases, and all forms of diabetes and related diseases for the treatment or prophylaxis is selected from the group consisting of polycystic ovarian syndrome 11. and / or a compound according to any one of claims 1 to 10 for improving lipid parameters, for improving β-cell function, and / or for delaying or preventing the progression of diabetic disease . A pharmaceutical composition comprising 一般式II:(HOHis)-(GLP-1ペプチド)の活性であり安定化した親薬物GLP-1化合物、またはその薬学的に許容される塩、アミド、もしくはエステルのインビボでの放出を達成するための、請求項1から9のいずれか一項に規定するそのプロドラッグを含む医薬組成物。 One general formula II: (HOHis) - achieving release of the active and is the parent drug GLP-1 compound was stabilized, or a pharmaceutically acceptable salt, amide or in vivo of the ester, the (GLP-1 peptide) A pharmaceutical composition comprising a prodrug thereof as defined in any one of claims 1 to 9 for doing so .
JP2014559183A 2012-03-01 2013-02-26 GLP-1 prodrug Active JP6300735B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12157638.3 2012-03-01
EP12157638 2012-03-01
PCT/EP2013/053796 WO2013127779A1 (en) 2012-03-01 2013-02-26 Glp-1 prodrugs

Publications (3)

Publication Number Publication Date
JP2015513544A JP2015513544A (en) 2015-05-14
JP2015513544A5 true JP2015513544A5 (en) 2016-03-03
JP6300735B2 JP6300735B2 (en) 2018-03-28

Family

ID=47748659

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014559183A Active JP6300735B2 (en) 2012-03-01 2013-02-26 GLP-1 prodrug

Country Status (6)

Country Link
US (1) US9452225B2 (en)
EP (1) EP2820038B1 (en)
JP (1) JP6300735B2 (en)
CN (1) CN104185639B (en)
ES (1) ES2810153T3 (en)
WO (1) WO2013127779A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016343775B2 (en) * 2015-10-28 2021-07-29 Tufts Medical Center Novel polypeptides with improved proteolytic stability, and methods of preparing and using same
KR102665710B1 (en) 2017-08-24 2024-05-14 노보 노르디스크 에이/에스 GLP-1 composition and its uses
CN109942696A (en) * 2017-12-21 2019-06-28 中国药科大学 Long-actingization glucagon-like-peptide-1 (GLP-1) analog and its application
CN112912100A (en) 2018-10-26 2021-06-04 诺和诺德股份有限公司 Stable semaglutide compositions and uses thereof
IL294521A (en) 2020-02-18 2022-09-01 Novo Nordisk As Glp-1 compositions and uses thereof
CN113336840B (en) * 2020-03-02 2022-09-23 武汉帕肽生物医药有限责任公司 Stapled peptides, methods of making and uses thereof
US20210318292A1 (en) * 2020-04-13 2021-10-14 Sensorium Bio, Inc. System and Method to Detect Small Molecules
JP7484018B2 (en) * 2020-11-06 2024-05-15 ノヴォ ノルディスク アー／エス GLP-1 PRODRUGS AND USES THEREOF
TW202346324A (en) 2022-05-10 2023-12-01 丹麥商諾佛 儂迪克股份有限公司 Prodrugs and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61143400A (en) * 1984-12-17 1986-07-01 Kenji Okawa Peptide like actinomycin d
US4966848A (en) * 1988-02-08 1990-10-30 The General Hospital Corporation Isolation, purification, characterization, cloning and sequencing of N α-acetyltransferase
US5223421A (en) * 1989-10-25 1993-06-29 The General Hospital Corporation Identification of methionine Nα-acetyltransferase
US5688489A (en) * 1995-09-15 1997-11-18 Resolution Pharmaceuticals, Inc. Non-receptor mediated imaging agents
FR2777283B1 (en) 1998-04-10 2000-11-24 Adir NOVEL GLUCAGON-PEPTIDE- 1 (7-37) ANALOGUE PEPTIDE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
SK1432004A3 (en) * 2001-10-01 2005-03-04 Eli Lilly And Company Medicament for reducing mortality and morbidity associated with critical illnesses
US8067362B2 (en) 2005-02-02 2011-11-29 Novo Nordisk As Insulin derivatives
EP2164466A1 (en) 2007-06-01 2010-03-24 Novo Nordisk A/S Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier
US8895694B2 (en) 2007-09-05 2014-11-25 Novo Nordisk A/S Glucagon-Like Peptide-1 derivatives and their pharmaceutical use
CN101220088B (en) * 2007-09-24 2012-01-25 中国人民解放军第四军医大学 Amalgamation protein of human glucagons-like peptide-1 and uses thereof
EP2214691B1 (en) 2007-10-30 2015-09-30 Indiana University Research and Technology Corporation Compounds exhibiting glucagon antagonist and glp-1 agonist activity
WO2009058662A2 (en) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Glucagon antagonists
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
WO2009099763A1 (en) * 2008-01-30 2009-08-13 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
WO2010071807A1 (en) 2008-12-19 2010-06-24 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
CA2747195A1 (en) 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Dipeptide linked medicinal agents
CN104311657B (en) 2009-12-16 2020-12-08 诺沃—诺迪斯克有限公司 Double acylated GLP-1 derivatives
KR20130102470A (en) * 2010-06-24 2013-09-17 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Amide based glucagon superfamily peptide prodrugs

Similar Documents

Publication Publication Date Title
JP2015513544A5 (en)
RU2012128547A (en) TWICE Acylated Derivatives GLP-1
JP2013530974A5 (en)
JP2011526886A5 (en)
WO2019143902A3 (en) Substituted heterocycles as antiviral agents
JP2013507439A5 (en)
WO2013002580A3 (en) Exendin-4 analogue pegylated with polyethylene glycol or derivative thereof, preparation method thereof, and pharmaceutical composition for preventing or treating diabetes, containing same as active ingredient
JP2013533227A5 (en)
RU2015147876A (en) ORAL DOSED FORM OF COMPOUNDS OF Glucagon-like PEPTIDE-1
JP2014503526A5 (en)
JP2018522843A5 (en)
TN2012000215A1 (en) Pharmaceutical compositions comprising a g l p -1 agonist and methionine
WO2009011544A3 (en) Insulinotropic peptide derivative wherein its n-terminal amino acid is modified
JP2013542247A5 (en)
MX355361B (en) Double-acylated glp-1 derivatives.
JP2017500289A5 (en)
MY174002A (en) Combination theraphy for the treatment of diabetes
EP2581376A4 (en) Matrinic acid/ matrine derivatives and preparation methods and uses thereof
RU2016135543A (en) NEW DERIVATIVES OF INSULIN AND THEIR APPLICATION IN MEDICINE
WO2009076173A3 (en) Fluorinated tripeptide hcv serine protease inhibitors
JP2018505146A5 (en)
JP2016532716A5 (en)
JP2016519106A5 (en)
JP2013520405A5 (en)
WO2011049908A3 (en) Bismacrokyclic compounds as hepatitis c virus inhibitors